AD1801 is an innovative project to develop disease modifying treatment of Alzheimer’s disease, targeting Apolipoprotein E (ApoE), a different molecule than those targeted in the projects BAN2401 and BAN2401 back-up.
In August 2018, BioArctic obtained exclusive rights to develop antibody treatments for Alzheimer’s disease from a research project jointly owned with Eisai. The partner Eisai has the rights to develop small molecule treatment from this research project with a different target than those in the projects BAN2401 and BAN2401 back-up.
In June 2020, BioArctic and University of Oslo, Institute of Clinical Medicine (IKM), signed a research collaboration agreement to increase the understanding of Apolipoprotein E (ApoE) as a drug target for Alzheimer’s disease. BioArctic will provide financial support for a two-year research position, with potential extension, and Professor Lars Nilsson at the Department of Pharmacology will be heading the research project at University of Oslo.
Apolipoprotein E is the major genetic risk factor for sporadic Alzheimer’s disease. The goals of the collaboration are to understand the mechanistic involvement of Apolipoprotein E in Alzheimer’s disease pathogenesis, and to generate pharmacological efficacy data with drug candidates. In the end, BioArctic hopes to be able to use the findings of the research collaboration to offer Alzheimer’s disease patients improved quality of life through better pharmacological treatment.